Advances and challenges in measuring hepatic glucose uptake with FDG PET: implications for diabetes research Jeremy Basset-SagarminagaTineke van de WeijerVera Schrauwen-Hinderling Review 15 December 2023 Pages: 407 - 419
The impact of taxing sugar-sweetened beverages on diabetes: a critical review José L. Peñalvo Review 04 January 2024 Pages: 420 - 429
Type 2 diabetes and succinate: unmasking an age-old molecule Sonia Fernández-VeledoAnna Marsal-BeltranJoan Vendrell Review Open access 05 January 2024 Pages: 430 - 442
Twenty years of participation of racialised groups in type 2 diabetes randomised clinical trials: a meta-epidemiological review Rabeeyah AhmedRussell J. de SouzaSonia S. Anand Article Open access 04 January 2024 Pages: 443 - 458
Impact of remission from type 2 diabetes on long-term health outcomes: findings from the Look AHEAD study Edward W. GreggHaiying Chenfor the Look AHEAD Research Group Article Open access 18 January 2024 Pages: 459 - 469
Dose–response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial Matthias BlüherJulio RosenstockAnita M. Hennige Article Open access 14 December 2023 Pages: 470 - 482
Cardiovascular and mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study Arunkumar KrishnanCarolin V. SchneiderSaleh A. Alqahtani Article Open access 20 December 2023 Pages: 483 - 493
Phenotype and predictors of insulin independence in adults presenting with diabetic ketoacidosis: a prospective cohort study Peter J. RaubenheimerJoanna SkeltonNaomi S. Levitt Article Open access 19 January 2024 Pages: 494 - 505
MTNR1B genotype and effects of carbohydrate quantity and dietary glycaemic index on glycaemic response to an oral glucose load: the OmniCarb trial Yoriko HeianzaTao ZhouLu Qi Article 05 December 2023 Pages: 506 - 515
Maternal and neonatal outcomes according to the timing of diagnosis of hyperglycaemia in pregnancy: a nationwide cross-sectional study of 695,912 deliveries in France in 2018 Nolwenn RegnaultElodie LebretonEmmanuel Cosson Article Open access 05 January 2024 Pages: 516 - 527
GLP-1 metabolite GLP-1(9–36) is a systemic inhibitor of mouse and human pancreatic islet glucagon secretion Nikhil R. GandasiRui GaoPatrik Rorsman Extended Article Open access 21 December 2023 Pages: 528 - 546
NRF2 is required for neonatal mouse beta cell growth by maintaining redox balance and promoting mitochondrial biogenesis and function Sharon Baumel-AlterzonLiora S. KatzDonald K. Scott Article 11 January 2024 Pages: 547 - 560
Glucagon-like peptide-1 receptor agonists reverse nerve morphological abnormalities in diabetic peripheral neuropathy Roshan DhanapalaratnamTushar IssarArun V. Krishnan Short Communication 08 January 2024 Pages: 561 - 566
Comments on the notion of false positivity in measurements of autoantibodies Valdemar GrillElin SørgjerdSofia Carlsson Letter 04 January 2024 Pages: 567 - 568
Comments on the notion of false positivity in measurements of autoantibodies. Reply to Grill V, Sørgjerd E, Hals I, Carlsson S [letter] Nicholas J. ThomasAngus G. Jones Letter 04 January 2024 Pages: 569 - 570